Loading…

UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX+RITUXIMAB RETREATMENT IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): PHASE 3 MURANO SUBSTUDY

Saved in:

Bibliographic Details
Published in:	Hematological oncology 2021-06, Vol.39 (S2)
Main Authors:	Wu, J. Q., Seymour, J. F., Eichhorst, B., Hillmen, P., Kipps, T., Langerak, A. W., Owen, C., Dubois, J., Mellink, C., van der Kevie‐Kersemaekers, A., Chyla, B., Jiang, Y., Boyer, M., Thadani‐Mulero, M., Lefebure, M., Kater, A. P.
Format:	Article
Language:	English
Subjects:	Chronic lymphocytic leukemia Genetics Immunotherapy Leukemia Lymphatic leukemia Monoclonal antibodies Rituximab Targeted cancer therapy
Citations:	Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!